United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
The Stock Market LLC | ||||
The Stock Market LLC | ||||
The Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(a) On February 14, 2022, Dr. Kumar Shiralagi, a director of Bannix Acquisition Corp. (the “Registrant”) informed the Board of Directors of the Registrant that he was resigning his position as director for personal reasons effective February 16, 2022. Dr. Shiralagi’s resignation was not due to any dispute with the Registrant.
(b) On February 14, 2022, the independent directors of the Registrant nominated Subbanarasimhaiah Arun to fill the vacancy created by the resignation of Dr. Shiralagi. His term will begin on February 16, 2022. Mr. Arun is expected to be appointed to the Audit, Compensation and Corporate Governance Committees of the Board of Directors. He will be appointed as Chairman of the Compensation Committee. Mr. Arun is a lawyer and will qualify as an independent director. There are no transactions between Mr. Arun and the Registrant of the type required to be disclosed by Item 404(a) of Regulation S-K.
(c) On February 16, 2022, Mr. Balaji Venugopal Bhat, an independent director, will cease to be the Chairman of the Compensation Committee and will be appointed as the Chairman of the Audit Committee. Mr. Bhat is a qualified Chartered Accountant and will qualify as an independent director and an audit committee financial expert.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 14, 2022 | ||
BANNIX ACQUISITION CORP. | ||
By: | /s/ Subash Menon | |
Name: Subash Menon | ||
Title: Chief Executive Officer |